INVENTIVA

Over 80 companies are actively developing treatments for Non-Alcoholic Steatohepatitis (NASH), with Inventiva Pharma and Cirius Therapeutics leading with Phase III candidates lanifibranor and MSDC-0602K respectively.

Inventiva and Hepalys Pharma have initiated the clinical development of lanifibranor in Japan, dosing the first participant in a Phase 1 trial to evaluate safety, tolerability, and pharmacokinetics.

Inventiva announces major restructuring, including significant workforce reduction and termination of preclinical programs, to extend financial runway through critical Phase III trial completion.

French biotech Inventiva announces major restructuring, planning to lay off 50% of employees and discontinue all preclinical research except for its lead MASH candidate lanifibranor.

Inventiva announces strategic pipeline prioritization, halting all preclinical research to focus exclusively on lanifibranor development for MASH treatment, with planned 50% workforce reduction.

Recent proof-of-concept study demonstrates Lanifibranor's significant efficacy in improving insulin sensitivity and reducing hepatic fat in MASLD patients with type 2 diabetes.

Inventiva has secured €21.4 million, completing the first tranche of a financing plan aimed at raising up to €348 million.

The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Phase 2 LEGEND trial data reveals lanifibranor, alone or with empagliflozin, significantly reduced HbA1c levels in MASH and T2D patients.

Inventiva has raised nearly €348 million to fund the Phase III clinical trial of lanifibranor, a small molecule drug, for the treatment of MASH.